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We used cDNA microarrays to explore the variation in expression of approximately 8,000 unique genes among the
60 cell lines used in the National Cancer Institute’s screen for anti-cancer drugs. Classification of the cell lines based
solely on the observed patterns of gene expression revealed a correspondence to the ostensible origins of the
tumours from which the cell lines were derived. The consistent relationship between the gene expression patterns
and the tissue of origin allowed us to recognize outliers whose previous classification appeared incorrect. Specific
features of the gene expression patterns appeared to be related to physiological properties of the cell lines, such
as their doubling time in culture, drug metabolism or the interferon response. Comparison of gene expression pat-
terns in the cell lines to those observed in normal breast tissue or in breast tumour specimens revealed features of
the expression patterns in the tumours that had recognizable counterparts in specific cell lines, reflecting the
tumour, stromal and inflammatory components of the tumour tissue. These results provided a novel molecular
characterization of this important group of human cell lines and their relationships to tumours in vivo.
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Introduction
Cell lines derived from human tumours have been extensively used
as experimental models of neoplastic disease. Although such cell
lines differ from both normal and cancerous tissue, the inaccessi-
bility of human tumours and normal tissue makes it likely that
such cell lines will continue to be used as experimental models for
the foreseeable future. The National Cancer Institute’s Develop-
mental Therapeutics Program (DTP) has carried out intensive
studies of 60 cancer cell lines (the NCI60) derived from tumours
from a variety of tissues and organs1–4. The DTP has assessed many
molecular features of the cells related to cancer and chemothera-
peutic sensitivity, and has measured the sensitivities of these 60 cell
lines to more than 70,000 different chemical compounds, includ-
ing all common chemotherapeutics (http://dtp.nci.nih.gov). A
previous analysis of these data revealed a connection between the
pattern of activity of a drug and its method of action. In particular,
there was a tendency for groups of drugs with similar patterns of
activity to have related methods of action3,5–7.
We used DNA microarrays to survey the variation in abun-
dance of approximately 8,000 distinct human transcripts in these
60 cell lines. Because of the logical connection between the func-
tion of a gene and its pattern of expression, the correlation of gene
expression patterns with the variation in the phenotype of the cell
can begin the process by which the function of a gene can be
inferred. Similarly, the patterns of expression of known genes can
reveal novel phenotypic aspects of the cells and tissues studied8–10.
Here we present an analysis of the observed patterns of gene
expression and their relationship to phenotypic properties of the
60 cell lines. The accompanying report11 explores the relationship
between the gene expression patterns and the drug sensitivity pro-
files measured by the DTP. The assessment of gene expression pat-
terns in a multitude of cell and tissue types, such as the diverse set
of cell lines we studied here, under diverse conditions in vitro and
in vivo, should lead to increasingly detailed maps of the human
gene expression program and provide clues as to the physiological
roles of uncharacterized genes11–16. The databases, plus tools for
analysis and visualization of the data, are available (http://genome-
www.stanford.edu/nci60 and http://discover.nci.nih.gov).
Results
We studied gene expression in the 60 cell lines using DNA
microarrays prepared by robotically spotting 9,703 human
cDNAs on glass microscope slides17,18. The cDNAs included
approximately 8,000 different genes: approximately 3,700 repre-
sented previously characterized human proteins, an additional
1,900 had homologues in other organisms and the remaining
2,400 were identified only by ESTs. Due to ambiguity of the iden-
tity of the cDNA clones used in these studies, we estimated that
approximately 80% of the genes in these experiments were cor-
rectly identified. The identities of approximately 3,000 cDNAs
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from these experiments have been sequence-verified, including
all of those referred to here by name.
Each hybridization compared Cy5-labelled cDNA reverse tran-
scribed from mRNA isolated from one of the cell lines with Cy3-
labelled cDNA reverse transcribed from a reference mRNA
sample. This reference sample, used in all hybridizations, was
prepared by combining an equal mixture of mRNA from 12 of
the cell lines (chosen to maximize diversity in gene expression as
determined primarily from two-dimensional gel studies2). By
comparing cDNA from each cell line with a common reference,
variation in gene expression across the 60 cell lines could be
inferred from the observed variation in the normalized Cy5/Cy3
ratios across the hybridizations.
To assess the contribution of artefactual sources of variation in
the experimentally measured expression patterns, K562 and
MCF7 cell lines were each grown in three independent cultures,
and the entire process was carried out independently on mRNA
extracted from each culture. The variance in the triplicate fluo-
rescence ratio measurements approached a minimum when the
fluorescence signal was greater than approximately 0.4% of the
measurable total signal dynamic range above background in
either channel of the hybridization. We selected the subset of
spots for which significant signal was present in both the numer-
ator and denominator of the ratios by this criterion to identify
the best-measured spots. The pair-wise correlation coefficients
for the triplicates of the set of genes that passed this quality con-
trol level (6,992 spots included for the MCF7 samples and 6,161
spots for K562) ranged from 0.83 to 0.92 (for graphs and details,
see http://genome-www.stanford.edu/nci60).
To make the orderly features in the data more apparent, we used
a hierarchical clustering algorithm19,20 and a pseudo-colour visu-
alization matrix3,21. The object of the clustering was to group cell
lines with similar repertoires of expressed genes and to group
genes whose expression level varied among the 60 cell lines in a
similar manner. Clustering was performed twice using different
subsets of genes to assess the robustness of the analysis. In one case
(Fig. 1), we concentrated on those genes that showed the most
variation in expression among the 60 cell lines (1,167 total). A sec-
ond analysis (Fig. 2) included all spots that were thought to be well
measured in the reference set (6,831 spots).
Gene expression patterns related to the histologic
origins of the cell lines
The most notable property of the clustered data was that cell lines
with common presumptive tissues of origin grouped together
(Figs 1a and 2). Cell lines derived from leukaemia, melanoma,
central nervous system, colon, renal and ovarian tissue were clus-
tered into independent terminal branches specific to their respec-
tive organ types with few exceptions. Cell lines derived from
non-small lung carcinoma and breast tumours were distributed
in multiple different terminal branches suggesting that their gene
expression patterns were more heterogeneous.
Many of these coherent cell line clusters were distinguished by
the specific expression of characteristic groups of genes
(Fig. 3a–d). For example, a cluster of approximately 90 genes was
highly expressed in the melanoma-derived lines (Fig. 3c). This set
was enriched for genes with known roles in melanocyte biology,
including tyrosinase and dopachrome tautomerase (TYR and
DCT; two subunits of an enzyme complex involved in melanin
synthesis22), MART1 (MLANA; which is being investigated as a
target for immunotherapy of melanoma23) and S100-β (S100B;
which has been used as an antigenic marker in the diagnosis of
breast
prostate
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Fig. 1 Gene expression patterns related to the tissue of origin of the cell lines. Two-dimen-
sional hierarchical clustering was applied to expression data from a set of 1,161 cDNAs
measured across 64 cell lines. The 1,161 cDNAs were those (of 9,703 total) with transcript
levels that varied by at least sevenfold (log2 (ratio) >2.8) relative to the reference pool in at
least 4 of 60 cell lines. This effectively selected genes with the greatest variation in expres-
sion level across the 60 cell lines (including those genes not well represented in the refer-
ence pool), and therefore highlighted those gene expression patterns that best
distinguished the cell lines from one another. Data from 64 hybridizations were used, one
for each cell line plus the two additional independent representations of each of the cell
lines K562 and MCF7. The two cell lines represented in triplicate were correspondingly
weighted for the gene clustering so that each of the 60 cell lines contributed equally to the
clustering. a, The cell-line dendrogram, with the terminal branches coloured to reflect the
ostensible tissue of origin of the cell line (red, leukaemia; green, colon; pink, breast; pur-
ple, prostate; light blue, lung; orange, ovarian; yellow, renal; grey, CNS; brown, melanoma;
black, unknown (NCI/ADR-RES)). The scale to the right of the dendrogram depicts the cor-
relation coefficient represented by the length of the dendrogram branches connecting
pairs of nodes. Note that the two triplets of replicated cell lines (K562 and MCF7) cluster
tightly together and were well differentiated from even the most closely related cell lines,
indicating that this clustering of cell lines is based on characteristic variations in their gene
expression patterns rather than artefacts of the experimental procedures. b, A coloured
representation of the data table, with the rows (genes) and columns (cell lines) in cluster
order. The dendrogram representing hierarchical relationships between genes was omit-
ted for clarity, but is available (http://genome-www.stanford.edu/nci60). The colour in each
cell of this table reflects the mean-adjusted expression level of the gene (row) and cell line
(column). The colour scale used to represent the expression ratios is shown. The labels
‘3a–3d’ in (b) refer to the clusters of genes shown in detail in Fig. 3.
a b c
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WEE1 PROTEIN KINASE HOMOLOG
ADD1 ADDUCIN 1 ALPHA
RFC4 REPLICATION FACTOR C
hnRNP-A0
E1B-AP5 E1B ASSOCIATED PROTEIN
PPP2CA PROTEIN PHOSHATASE 2  CAT.  ALPHA
CDC25C CELL DIVISION CYCLE 25B
MKI67 ANTIGEN
TOP2A DNA TOPOISOMERASE II ALPHA
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RPL29 RIBOSOMAL PROTEIN L29
STAT3
RPL3 RIBOSOMAL PROTEIN L3 
EIF4B INITIATION FACTOR 4B 
EIF4B INITIATION FACTOR 4B 
RPL3 RIBOSOMAL PROTEIN L3
RPS13 RIBOSOMAL PROTEIN S13
RPL31 RIBOSOMAL PROTEIN L31
RPL27A RIBOSOMAL PROTEIN L27A
EEF1B1 ELONGATION FACTOR 1-BETA
RPL27 RIBOSOMAL PROTEIN L27
RPLP0 RIBOSOMAL PROTEIN P0 
HSPB1 HEAT SHOCK PROTEIN 27KD
DUPLICATE SPINAL MUSCULAR ATROPHY
RPL3 RIBOSOMAL PROTEIN L3
BTF3 BASIC TRANSCRIPTION FACTOR 3
RPL41 RIBOSOMAL PROTEIN L41
EEF1A1 ELONGATION FACTOR 1-ALPHA-1
EEF1A1 ELONGATION FACTOR 1-ALPHA-1
EEF1A1 ELONGATION FACTOR 1-ALPHA-1
IMPDH2 INOSINE MONOPHOSPHATE DEHYDROGENASE2
PP2A PROTEIN PHOSPHATASE 2A REG. 2 BETA 
RPL32 RIBOSOMAL PROTEIN L32
RPLSA RIBOSOMAL PROTEIN SA
RPLS12 RIBOSOMAL PROTEIN S12
RPLS8 RIBOSOMAL PROTEIN S8
RPLS3 RIBOSOMAL PROTEIN S3
CTCF TRANSCRIPTIONAL REPRESSOR 
UBCH5C UBIQUITIN CONJUGATING ENZYME
MAD2L1 MAD2-LIKE 1
CCNA2 CYCLIN A2
DDX5 DEAD/H BOX RNA HELICASE
hSNF2H SMARCA5  (SWI/SNF RELATED)
SFPQ SPLICING FACTOR SFPQ
SFPQ SPLICING FACTOR SFPQ
SFRS1 SPLICING FACTOR 2
hnRNP-U 
hnRNP-G
hnRNP-G
RPS8 RIBOSOMAL PROTEIN S8
SFRS3 SPLICING FACTOR
CENPC1 CENTROMERE PROTEIN C1
PTMA PROTHYMOSIN ALPHA
RPLS3A RIBOSOMAL PROTEIN S3A
MCM6 p105MCM
IFIT2 INTERFERON-INDUCED 54 KD
MTAP44 HEPATITUS C  ASSOCIATED p44
CASP4 CASPASE 4
SP140 NUCLEAR BODY PROTEIN
IFI41 INTERFERON INDUCED 41 KD
MX1 MYXOVIRUS RESISTANCE 1
OAS1 2'-5' OLIGOADENYLATE SYNTHETASE
PLSCR1 PHOSPHOLIPID SCRAMBLASE
RAB10 RAS ONCOGENE FAMILY
AKR1C1 ALDO-KETO REDUCTASE FAMILY1, C1*
AKR1C1 ALDO-KETO REDUCTASE FAMILY1, C1*
AKR1C4 ALDO-KETO REDUCTASE FAMILY1, C4*
GLCLR GAMMA GLUTAMYL-CYSTEINE SYNTHETASE*
TXNRD1 THIOREDOXIN REDUCTASE*
TXN THIOREDOXIN*
AF1q TRANSMEMBRANE PROTEIN
SHP NUCLEAR HORMONE RECEPTOR 
ABCC1 ATP-BINDING CASSETE, SUB-FAMILY C (MRP1)*
ADTB2 ADAPTIN BETA 2
ADTB2 ADAPTIN BETA 2
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Fig. 2 Gene expression patterns related to
other cell-line phenotypes. a, We applied
two-dimensional hierarchical clustering to
expression data from a set of 6,831 cDNAs
measured across the 64 cell lines. The 6,831
cDNAs were those with a minimum fluores-
cence signal intensity of approximately 0.4%
of the dynamic range above background in
the reference channel in each of the six
hybridizations used to establish reproducibil-
ity. This effectively selected those spots that
provided the most reliable ratio measure-
ments and therefore identified a subset of
genes useful for exploring patterns comprised
of those whose variation in expression across
the 60 cell lines was of moderate magnitude.
b, Cluster-ordered data table. c, Doubling
time of cell lines. Cell lines are given in cluster
order. Values are plotted relative to the mean.
Doubling times greater than the mean are
shown in green, those with doubling time less
than the mean are shown in red. d, Three
related gene clusters that were enriched for
genes whose expression level variation was
correlated with cell line proliferation rate.
Each of the three gene clusters (clustered
solely on the basis of their expression pat-
terns) showed enrichment for sets of genes
involved in distinct functional categories (for
example, ribosomal genes versus genes
involved in pre-RNA splicing). e, Gene cluster
in which all characterized and sequence-veri-
fied cDNAs encode genes known to be regu-
lated by interferons. f, Gene cluster enriched
for genes that have been implicated in drug
metabolism (indicated by asterisks). A further
property of the gene clustering evident here
and in Fig. 2 is the strong tendency for redun-
dant representations of the same gene to
cluster immediately adjacent to one another,
even within larger groups of genes with very
similar expression patterns. In addition to
illustrating the reproducibility and consis-
tency of the measurements, and providing
independent confirmation of many of our
measurements, this property also demon-
strates that these, and probably all, genes
have nearly unique patterns of variation
across the 60 cell lines. If this were not the
case, and multiple genes had identical pat-
terns of variation, we would not expect to be
able to distinguish, by clustering on the basis
of expression variation, duplicate copies of
individual genes from the other genes with
identical expression patterns.
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melanoma). LOXIMVI, the seventh line designated as melanoma
in the NCI60, did not show this characteristic pattern. Although
isolated from a patient with melanoma, LOXIMVI has previously
been noted to lack melanin and other markers useful for identifi-
cation of melanoma cells1.
Paradoxically, two related cell lines (MDA-MB435 and MDA-
N), which were derived from a single patient with breast cancer
and have been conventionally regarded as breast cancer cell lines,
shared expression of the genes associated with melanoma. MDA-
MB435 was isolated from a pleural effusion in a patient with
metastatic ductal adenocarcinoma of the breast24,25. It remains
possible that the origin of the cell line was a breast cancer, and that
its gene expression pattern is related to the neuroendocrine fea-
tures of some breast cancers26. But our results suggest that this cell
line may have originated from a melanoma, raising the possibility
that the patient had a co-existing occult melanoma.
The higher-level organization of the cell-line treein which
groups span cell lines from different tissue typesalso reflected
shared biological properties of the tissues from which the cell
lines were derived. The carcinoma-derived cell lines were divided
into major branches that separated those that expressed genes
characteristic of epithelial cells from those that expressed genes
more typical of stromal cells. A cluster of genes is shown (Fig. 3b)
that is most strongly expressed in cell lines derived from colon
carcinomas, six of seven ovarian-derived cell lines and the two
breast cancer lines positive for the oestrogen receptor. The named
genes in this cluster have been implicated in several aspects of
epithelial cell biology27. The cluster was enriched for genes whose
products are known to localize to the basolateral membrane of
epithelial cells, including those encoding components of
adherens complexes (for example, desmoplakin (DSP),
periplakin (PPL) and plakoglobin (JUP)), an epithelial-
expressed cell-cell adhesion molecule (M4S1) and a sodium/
hydrogen ion exchanger28–31 (SLC9A1). It also contained genes
that encode putative transcriptional regulators of epithelial mor-
phogenesis, a human homologue of a Drosophila melanogaster
epithelial-expressed tumour suppressor (LLGL1) and a homeo-
box gene thought to control calcium-mediated adherence in
epithelial cells32,33 (MSX2).
In contrast, a separate, major branch of the cell-line dendro-
gram (Fig. 1a) included all glioblastoma-derived cell lines, all
renal-cell-carcinoma–derived cell lines and the remaining carci-
noma-derived lines. The characteristic set of genes expressed in
this cluster included many whose products are involved in stro-
mal cell functions (Fig. 3d). Indeed, the two cell lines originally
described as ‘sarcoma-like’ in appearance (Hs578T, breast carci-
nosarcoma, and SF539, gliosarcoma) expressed most of these
genes34,35. Although no single gene was uniformly characteristic
of this cluster, each cell line showed a distinctive pattern of
expression of genes encoding proteins with roles in synthesis or
modification of the extracellular matrix (for example, caldesmon
(CALD1), cathepsins, thrombospondin (THBS), lysyl oxidase
(LOX) and collagen subtypes). Although the ovarian and most
non-small-cell-lung–derived carcinomas expressed genes charac-
teristic of both epithelial cells and stromal cells, they probably
clustered with the CNS and renal cell carcinomas in this analysis
because genes characteristically expressed in stromal cells were
more abundantly represented in this gene set.
Physiological variation reflected 
in gene expression patterns
A cluster diagram of 6,831 genes (Fig. 2) is useful for exploring
clusters of genes whose variation in mRNA levels was not obvi-
ously attributable to cell or tissue type. We identified some gene
clusters that were enriched for genes involved in specific cellular
processes; the variation in their expression levels may reflect cor-
responding differences in activity of these processes in the cell
lines. For example, a cluster of 1,159 genes (Fig. 2a) included
many whose products are necessary for progression through the
cell cycle (such as CCNA1, MCM106 and MAD2L1), RNA pro-
cessing and translation machinery (such as RNA helicases,
hnRNPs and translation elongation factors) and traditional
pathologic markers used to identify proliferating cells (MKI67).
Within this large cluster were smaller clusters enriched for genes
with more specialized roles. One cluster was highly enriched for
numerous ribosomal genes, whereas another was more enriched
for genes encoding RNA-splicing factors. The variation in
expression of these ribosomal genes was significantly correlated
with variation in the cell doubling time (correlation coefficient of
0.54), supporting the notion that the genes in this cluster were
regulated in relation to cell proliferation rate or growth rate in
these cell lines.
In a smaller gene cluster (Fig. 2d), all of the named genes were
previously known to be regulated by interferons13,36. Additional
groups of interferon-regulated genes showed distinct patterns of
expression (data not shown), suggesting that the NCI60 cell lines
exhibited variation in activity of interferon-response pathways,
which was reflected in gene expression patterns36.
Another cluster (Fig. 2e) contained several genes encoding
proteins with possible interrelated roles in drug metabolism,
including glutamate-cysteine ligase (GLCLC, the enzyme respon-
sible for the rate limiting step of glutathione synthesis), thiore-
doxin (TXN) and thioredoxin reductase (TXNRD1; enzymes
involved in regulating redox state in cells), and MRP1 (a drug
transporter known to efficiently transport glutathione-conju-
gated compounds37). The elevated expression of this set of genes
in a subset of these cell lines may reflect selection for resistance to
chemotherapeutics.
Cell lines facilitate interpretation of gene expression
patterns in complex clinical samples
Like many other types of cancer, tumours of the breast typically
have a complex histological organization, with connective tissue
and leukocytic infiltrates interwoven with tumour cells. To
explore the possibility that variation in gene expression in the
tumour cell lines might provide a framework for interpreting the
expression patterns in tumour specimens, we compared RNA
isolated from two breast cancer biopsy samples, a sample of nor-
mal breast tissue and the NCI60 cell lines derived from breast
cancers (excluding MDA-MB-435 and MDA-N) and leukaemias
(Fig. 4). This clustering highlighted features of the gene expres-
sion pattern shared between the cancer specimens and individual
cell lines derived from breast cancers and leukaemias.
The genes encoding keratin 8 (KRT8) and keratin 19 (KRT19),
as well as most of the other ‘epithelial’ genes defined in the com-
plete NCI60 cell line cluster, were expressed in both of the biopsy
samples and the two breast-derived cell lines, MCF-7 and T47D,
expressing the oestrogen receptor, suggesting that these tran-
scripts originated in tumour cells with features similar to those of
luminal epithelial cells (Fig. 5a). Expression of a set of genes char-
acteristic of stromal cells, including collagen genes (COL3A1,
COL5A1 and COL6A1) and smooth muscle cell markers
(TAGLN), was a feature shared by the tumour sample and the
stromal-like cell lines Hs578T and BT549 (Fig. 5b). This feature
of the expression pattern seen in the tumour samples is likely to
be due to the stromal component of the tumour. The tumours
also shared expression of a set of genes (Fig. 5c) with the multiple
myeloma cell line (RPMI-8226), notably including
immunoglobulin genes, consistent with the presence of B cells
in the tumour (this was confirmed by staining with anti-
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PRKCB1 PROTEIN KINASE C BETA 1
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MSX2 MSH HOMEOBOX HOMOLOG
HE4 EXTRACELLULAR PROTEINASE INHIBITOR
TPD52L1 TUMOR PROTEIN D52-LIKE 1
NUCB2 DNA-BINDING PROTEIN NEFA
NUCB2 DNA-BINDING PROTEIN NEFA
ANXA3 ANNEXIN III
KRT7 KERATIN 7
KRT8 KERATIN 8
LAMA3 LAMININ ALPHA 3
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LYZ LYSOZYME
CLDN4 CLAUDIN 4
JUP PLAKOGLOBIN
DSP DESMOPLAKIN
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ITGB4 INTEGRIN BETA-4
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 epithelial cluster (15 ESTs)
LAMA4 LAMININ ALPHA 4
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A2M ALPHA-2-MACROGLOBULIN
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ERDA3 CAGH3
ERDA3 CAGH3
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GM6B
MLANA MELANOMA ANTIGEN RECOGNIZED BY T-CELLS
SIAT8A ALPHA2,8-SIALYLTRANSFERASE
TYRP1 TYROSINASE-RELATED PROTEIN 1
EDNRB ENDOTHELIN RECEPTOR TYPE B
S100B S-100 BETA
MUTYH MUTY HOMOLOG
TYR TYROSINASE
DCT DOPACHROME TAUTOMERASE
RXRG RETINOID  X RECEPTOR GAMMA
ACP5 ACID PHOSPHATASE TYPE 5
SIAT6 ALPHA2,3-SIALYLTRANSFERASE
ART3 MONO-ADP-RIBOSYLTRANSFERASE
SCRAPIE RESPONSIVE PROTEIN 1
BCHE BUTYRYLCHOLINESTERASE
MBP MYELIN BASIC PROTEIN
MBP MYELIN BASIC PROTEIN 
PTPRZ1 TYROSINE PHOSPHATASE ZETA
G2 PROTEIN
CMOAT
CMOAT
CMOAT
 melanoma cluster (16 ESTs)
CDC2L1 CELL DIVISION CYCLE 2-LIKE 1
NRIP1 NUCLEAR FACTOR RIP140
TGFBR2 TRANSFORMING GROWTH FACTOR BETA RECEPTOR II
LTBR LYMPHOTOXIN-BETA RECEPTOR
CBP2 COLLAGEN BINDING PROTEIN 2
FKHL4 FORKHEAD RELATED 4
ANXA8 ANNEXIN VIII
CTSL CATHEPSIN L
COL5A2 COLLAGEN TYPE V ALPHA 2
COL4A1 COLLAGEN TYPE IV  ALPHA-1 
COL4A1 COLLAGEN TYPE IV  ALPHA-1 
PDGFRA ALPHA PDGF RECEPTOR
THY1
THY1
FBN1 FIBRILLIN 1
FBN1 FIBRILLIN 1
PAI1 PLASMINOGEN ACTIVATOR INHIBITOR TYPE I
PAI1 PLASMINOGEN ACTIVATOR INHIBITOR TYPE I
DPYSL3 DIHYDROPYRIMIDINASE RELATED PROTEIN 3
DPYSL3 DIHYDROPYRIMIDINASE RELATED PROTEIN 3
DAB2
DAB2
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SGK
SGK
MIG2 MITOGEN INDUCIBLE GENE 2
LAMC1 LAMININ GAMMA 1
ARHE RAS HOMOLOG E
ITGB5 INTEGRIN BETA-5
TM4SF1 TUMOR-ASSOCIATED ANTIGEN L6
ALCAM ACTIVATED LEUCOCYTE CELL ADHESION MOLECULE
EPHA2 ECK KINASE
CAPN2 CALPAIN 2
ANXA2 ANNEXIN II
FAK FOCAL ADHESION KINASE
TJP1 TIGHT JUNCTION PROTEIN 1
THBS1 THROMBOSPONDIN 1
CNN3 CALPONIN 3
CTGF CONNECTIVE TISSUE GROWTH FACTOR
IGFBP10
LOX LYSYL OXIDASE
TPM1 TROPOMYOSIN ALPHA
TPM1 TROPOMYOSIN ALPHA
COL4A1 COLLAGEN TYPE IV ALPHA 1
COL4A1 COLLAGEN TYPE IV ALPHA 1
CAV1 CAVEOLIN
CAV1 CAVEOLIN
SNK SERUM-INDUCIBLE KINASE
AXL RECEPTOR
FGF2 FIBROBLAST GROWTH FACTOR 2
FGF2 FIBROBLAST GROWTH FACTOR 2 
GJA1 CONNEXIN 43
CSF1 COLONY-STIMULATING FACTOR 1
CALD1 CALDESMON
CALD1 CALDESMON
CALD1 CALDESMON
CUTL1 CUT DROSOPHILA-LIKE 1
FHL2 DRAL
CDH2 CADHERIN 2
PLOD2 LYSYL HYDROXYLASE 2
GEM GTPASE
FGF1 FIBROBLAST GROWTH FACTOR 1
PLCB4 PHOSPHOLIPASE C BETA 4
HSPB2 HEAT SHOCK 27KD PROTEIN 2
BFGFR BASIC FIBROBLAST GROWTH FACTOR RECEPTOR
NERF-2 ETS-RELATED FACTOR
PLAUR PLASMINOGEN ACTIVATOR UROKINASE RECEPTOR
FN1 FIBRONECTIN 1 (9 replicates)
IL6 INTERLEUKIN 6 
CLU CLUSTERIN
EFEMP1 EXTRACELLULAR MATRIX PROTEIN 1
EFEMP1 EXTRACELLULAR MATRIX PROTEIN 1
MCP1 MONOCYTE CHEMOTACTIC PROTEIN 1
SPOCK SPARK/OSTEONECTIN
INHBA INHIBIN BETA A
KRT17 KERATIN 17
TAGLN TRANSGELIN (SM22-ALPHA)
KRT14 KERATIN 14
EDN1 ENDOTHELIN 1
LMO7 LIM DOMAIN ONLY 7
EFNB2 EFRIN-B2
5T4-AG TROPHOBLAST GLYCOPROTEIN
SDC1 SYNDECAN 1
F3 THROMBOPLASTIN
F3 THROMBOPLASTIN
PSG4 PREGNANCY-SPECIFIC BETA-1 GLYCOPROTEIN 4
PSG7 PREGNANCY-SPECIFIC BETA 1-GLYCOPROTEIN 7
TGM2 TRANSGLUTAMINASE 2
ANPEP ALANYL AMINOPEPTIDASE
MUC18 MELANOMA ADHESION MOLECULE
MUC18 MELANOMA ADHESION MOLECULE
NTRKR1 NEUROTROPHIC TYR KINASE RECEPTOR-RELATED 1
NR3C1 GLUCOCORTICOID RECEPTOR
RARB RETINOIC ACID RECEPTOR BETA
CDH13 H-CADHERIN
CDH13 H-CADHERIN
OPCML OPIOID BINDING PROTEIN
IL1B INTERLEUKIN 1 BETA
ESM1 ENDOTHELIAL-CELL SPECIFIC 1
C3 COMPLEMENT
IF I FACTOR COMPLEMENT
VTN VITRONECTIN
SLPI ANTILEUKOPROTEINASE 1
HSD3B1 HYDROXY-DELTA-5-STEROID DEHYDROGENASE
HSD3B1 HYDROXY-DELTA-5-STEROID DEHYDROGENASE
MNDA MYELOID CELL NUCLEAR DIFFERENTIATION ANTIGEN
TNFAIP2 TNF ALPHA-INDUCED PROTEIN 2 
CP CERULOPLASMIN
SPON1 SPONDIN 1
SPON1 SPONDIN 1
IL1R1 INTERLEUKIN-1 RECEPTOR TYPE I
TFPI2 TISSUE FACTOR PATHWAY INHIBITOR 2
GRO2
VACAM1 VASCULAR CELL ADHESION MOLECULE 1
 mesenchymal cluster (67 ESTs)
EPB41L2 PROTEIN 4.1-G LIKE 2
a
b
c
d
Fig. 3 Gene clusters related to tissue characteristics in the cell lines. Enlargements of the regions of the cluster diagram in Fig. 1 showing gene clusters enriched
for genes expressed in cell lines of ostensibly similar origins. a, Cluster of genes highly expressed in the leukaemia-derived cell lines. Two sub-clusters distinguish
genes that were expressed in most leukaemia-derived lines from those expressed exclusively in the eryroblastoid line, K562 (note that the triplicate hybridiza-
tions cluster together). b, Cluster of genes highly expressed in all colon (7/7) cell lines and all breast-derived cell lines positive for the oestrogen receptor (2/2). This
set of genes was also moderately expressed in most ovarian lines (5/6) and some non-small-cell-lung (4/6) lines, but was expressed at a lower level in all renal-can-
cer–derived lines. c, Cluster of genes highly expressed in most melanoma-derived lines (6/7) and two related lines ostensibly derived from breast cancer (MDA-
MB435 and MDA-N). d, Cluster of genes highly expressed in all glioblastoma (6/6) lines and most lines derived from renal-cell carcinoma (7/8), and more
moderately expressed in a subset of carcinoma-derived lines. In all panels, names are shown only for all known genes whose identities were independently re-
verified by sequencing. The number of sequence-validated ESTs within the cluster is indicated below the cluster in parentheses. The position of gene names in the
adjacent list only approximates their position in the cluster diagram as indicated by the lines connecting the colour chart with the gene list. Complete cluster
images with all gene names and accession numbers are available (http://genome-www.stanford.edu/nci60).
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immunoglobulin antibodies; data not shown). Therefore, dis-
tinct sets of genes with co-varying expression among the samples
(Fig. 4, arrow) appear to represent distinct cell types that can be
distinguished in breast cancer tissue. A fourth cluster of genes,
more highly expressed in all of the cell lines than in any of the
clinical specimens, was enriched for genes present in the ‘prolif-
eration’ cluster described above (Fig. 5d). The variation in
expression of these genes likely paralleled the difference in prolif-
eration rate between the rapidly cycling cultured cell lines and the
much more slowly dividing cells in tissues.
Discussion
Newly available genomics tools allowed us to explore variation in
gene expression on a genomic scale in 60 cell lines derived from
diverse tumour tissues. We used a simple cluster analysis to iden-
tify the prominent features in the gene expression patterns that
appeared to reflect ‘molecular signatures’ of the tissue from
which the cells originated. The histological characteristics of the
cell lines that dominated the clustering were pervasive enough
that similar relationships were revealed when alternative subsets
of genes were selected for analysis. Additional features of the
expression pattern may be related to variation in physiological
attributes such as proliferation rate and activity of interferon-
response pathways.
The properties of the tumour-derived cell lines in this study
have presumably all been shaped by selection for resistance to
host defences and chemotherapeutics and for rapid proliferation
in the tissue culture environment of synthetic growth media, fetal
bovine serum and a polystyrene substratum. But the primary
identifiable factor accounting for variation in gene expression
patterns among these 60 cell lines was the identity of the tissue
from which each cell line was ostensibly derived. For most of the
cell lines we examined, neither physiological nor experimental
adaptation for growth in culture was sufficient to overwrite the
gene expression programs established during differentiation in
vivo. Nevertheless, the prominence of mesenchymal features in
the cell lines isolated from glioblastomas and carcinomas may
reflect a selection for the relative ease of establishment of cell
lines expressing stromal characteristics, perhaps combined with
physiological adaptation to tissue culture conditions38–40.
Biological themes linking genes with related expression pat-
terns may be inferred in many cases from the shared attributes of
known genes within the clusters. Uncharacterized cDNAs are
likely to encode proteins that have roles similar to those of the
known gene products with which they appear to be co-regulated.
Still, for several clusters of genes, we were unable to discern a com-
mon theme linking the identified members of the cluster. Further
exploration of their variation in expression under more diverse
conditions and more comprehensive investigation of the physiol-
ogy of the NCI60 cells may provide insight10. The relationship of
the gene expression patterns to the drug sensitivity patterns mea-
sured by the DTP is an example of linking variation in gene
expression with more subtle and diverse phenotypic variation11.
The patterns of gene expression measured in the NCI60 cell
lines provide a framework that helps to distinguish the cells that
express specific sets of genes in the histologically complex breast
cancer specimens41. Although it is now feasible to analyse gene
expression in micro-dissected tumour specimens42,43, this obser-
vation suggests that it will be possible to explore and interpret
some of the biology of clinical tumour samples by sampling them
intact. As is useful in conventional morphological pathology, one
might be able to observe interactions between a tumour and its
microenvironment in this way. These relationships will be clari-
fied by suitable analysis of gene expression patterns from intact as
well as dissected tumours12,14,15,41.
Methods
cDNA clones. We obtained the 9,703 human cDNA clones (Research Genet-
ics) used in these experiments as bacterial colonies in 96-well microtitre
plates9. Approximately 8,000 distinct Unigene clusters (representing nomi-
nally unique genes) were represented in this set of clones. All genes identi-
fied here by name represent clones whose identities were confirmed by re-
sequencing, or by the criteria that two or more independent cDNA clones
ostensibly representing the same gene had nearly identical gene expression
patterns. A single-pass 3´ sequence re-verification was attempted for every
clone after re-streaking for single colonies. For a subset of genes for which
quality 3´ sequence was not obtained, we attempted to confirm identities by
5´ sequencing. Of the subset of clones selected for 5´ sequence verification
on the basis of an interesting pattern of expression (888 total), 331 were cor-
rectly identified, 57, incorrectly identified, and 500, indeterminate (poor
quality sequence). We estimated that 15%–20% of array elements contained
DNA representing more than one clone per well. So far, the identities of
∼3,000 clones have been verified. The full list of clones used and their nomi-
nal identities are available (gene names preceded by the designation “SID#”
(Stanford Identification) represent clones whose identities have not yet been
verified; http://genome-www.stanford.edu:8000/nci60).
Production of cDNA microarrays. The arrays used in this experiment were
produced at Synteni Inc. (now Incyte Pharmaceuticals). Each insert was
amplified from a bacterial colony by sampling 1 µl of bacterial media and
performing PCR amplification of the insert using consensus primers for
the three plasmids represented in the clone set (5´–TTGTAAAACGACG
GCCAGTG–3´, 5´–CACACAGGAAACAGCTATG–3´). Each PCR product
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Fig. 4 Comparison of the gene expression patterns in clinical breast cancer
specimens and cultured breast cancer and leukaemia cell lines. a, Two-dimen-
sional hierarchical clustering applied to gene expression data for two breast
cancer specimens, a lymph node metastasis from one patient, normal breast
and the NCI60 breast and leukaemia-derived cell lines. The gene expression
data from tissue specimens was clustered along with expression data from a
subset of the NCI60 cell lines to explore whether features of expression pat-
terns observed in specific lines could be identified in the tissue samples. Labels
indicate gene clusters (shown in detail in Fig. 5) that may be related to specific
cellular components of the tumour specimens. b, Breast cancer specimen 16
stained with anti-keratin antibodies, showing the complex mix of cell types
characteristically found in breast tumours. The arrows highlight the different
cellular components of this tissue specimen that were distinguished by the
gene expression cluster analysis (Fig. 5).
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(100 µl) was purified by gel exclusion, concentrated and resuspended in
3×SSC (10 µl). The PCR products were then printed on treated glass
microscope slides using a robot with four printing tips. Detailed protocols
for assembling and operating a microarray printer, and printing and exper-
imental application of DNA microarrays are available (http://cmgm.
stanford.edu/pbrown).
Preparation of mRNA and reference pool. Cell lines were grown from NCI
DTP frozen stocks in RPMI-1640 supplemented with phenol red, glutamine
(2 mM) and 5% fetal calf serum. To minimize the contribution of variations
in culture conditions or cell density to differential gene expression, we grew
each cell line to 80% confluence and isolated mRNA 24 h after transfer to
fresh medium. The time between removal from the incubator and lysis of the
cells in RNA stabilization buffer was minimized (<1 min). Cells were lysed in
buffer containing guanidium isothiocyanate and total RNA was purified
with the RNeasy purification kit (Qiagen). We purified mRNA as needed
using a poly(A) purification kit (Oligotex, Qiagen) according to the manu-
facturer’s instructions. Denaturing agarose gel electrophoresis assessed the
integrity and relative contamination of mRNA with ribosomal RNA.
The breast tumours were surgically excised from patients and rapidly
transported to the pathology laboratory, where samples for microarray
analysis were quickly frozen in liquid nitrogen and stored at –80 °C until
use. A frozen tumour specimen was removed from the freezer, cut into
small pieces (∼50–100 mg each), immediately placed into 10–12 ml of Tri-
zol reagent (Gibco-BRL) and homogenized using a PowerGen 125 Tissue
Homogenizer (Fisher Scientific), starting at 5,000 r.p.m. and gradually
increasing to ∼20,000 r.p.m. over a period of 30–60 s. We processed the Tri-
zol/tumour homogenate as described in the Trizol protocol, including an
initial step to remove fat. Once total RNA was obtained, we isolated mRNA
with a FastTrack 2.0 kit (Invitrogen) using the manufacturer’s protocol for
isolating mRNA starting from total RNA. The normal breast samples were
obtained from Clontech.
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RARB RETINOIC ACID RECEPTOR BETA 
SPOCK SPARC/OSTEONECTIN
COL5A4 COLLAGEN TYPE V ALPHA 2
HF1 H FACTOR COMPLEMENT LIKE 1
THY-1 ANTIGEN
ERDA3 CAG REPEAT DOMAIN
UGT2B10 UDP-GLYCOSYLTRANSFERASE 2 B10
DUSP1 DUAL SPECIFICITY PHOSPHATASE 1 (5 replicates)
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PSMA5 PROTEASOME SUBUNIT ALPHA 5
CDC25B CELL DIVISION CYCLE 25B 
 proliferation cluster
CD33 ANTIGEN
MNDA MYELOID NUCLEAR DIFFERENTIATION ANTIGEN
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KYNU L-KYNURENINE HYDROLASE
EPHA1 TYROSINE KINASE RECEPTOR EPH
PLML PHOSPHOLEMMAN-LIKE
TGFB3 TRANSFORMING GROWTH FACTOR BETA 3 
SLC9A1 SOLUTE CARRIER FAMILY 9 
DSP DESMOPLAKIN
M4S1 GA733-2 (Ep-CAM)
DDR1 DISCOIDIN DOMAIN RECEPTOR
CLDN4 CLAUDIN 4
KRT8 KERATIN 8
CACNA1D CALCIUM CHANNEL L-TYPE ALPHA-1
PPL PERIPLAKIN
TPD52L1 TUMOR PROTEIN D52-LIKE 1
GCL GRANCALCIN
LLGL2 HUMAN GIANT LARVAE HOMOLOG
VDUP1 BRAIN-EXPRESSED HHCPA78 HOMOLOG
DLG3 NEUROENDOCRINE-DLG
MSX2 MSH HOMEOBOX HOMOLOG
tumour cell cluster
ELF3 EPITHELIAL TRANSCRIPTION FACTOR ESE-1B 
VDUP1 BRAIN-EXPRESSED HHCPA78 HOMOLOG
DSP DESMOPLAKIN
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THY1 ANTIGEN
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SGK SERUM/GLUCOCORTICOID REGULATED KINASE
CALD1 CALDESMON 1
EFEMP1 EXTRACELLULAR PROTEIN  S1-5
TPM1 TROPOMYOSIN ALPHA
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Fig. 5 Histologic features of breast cancer biopsies can be recognized and parsed based on gene expression patterns. Enlargements of the regions of the cluster
diagram in Fig. 4 showing gene clusters enriched for genes expressed in different cell types in the breast cancer specimens, as distinguished by clustering with the
cultured cell lines. a, A cluster including many genes characteristic of epithelial cells expressed in cell lines (T47D and MCF7) derived from breast cancer positive for
the oestrogen receptor and tumours. b, Genes expressed in cell lines derived from breast cancer with stromal cell characteristics (Hs578T and BT549) and tumour
specimens. Expression of these genes in the tumour samples may reflect the presence of myofibroblasts in the cancer specimen stroma. c, Genes expressed in leuko-
cyte-derived cell lines, showing common leukocyte, and separate ‘myeloid’ and ‘B-cell’, gene clusters. d, Genes that were relatively highly expressed in all cell lines
compared with the tumour specimens and normal breast. The higher expression of this set of genes involved in cell cycle transit in the cell lines is likely to reflect the
higher proliferative rate of cells cultured in the presence of serum compared with the average proliferation rate of cells in the biopsied tissue.
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We combined mRNA from the following cells in equal quantities to
make the reference pool: HL-60 (acute myeloid leukaemia) and K562
(chronic myeloid leukaemia); NCI-H226 (non-small-cell-lung); COLO
205 (colon); SNB-19 (central nervous system); LOX-IMVI (melanoma);
OVCAR-3 and OVCAR–4 (ovarian); CAKI-1 (renal); PC-3 (prostate); and
MCF7 and Hs578T (breast). The criterion for selection of the cell lines in
the reference are described in detail in the accompanying manuscript12.
Doubling-time calculations. We calculated doubling times based on rou-
tine NCI60 cell line compound screening data; and they reflect the dou-
bling times for cells inoculated into 96-well plates at the screening inocula-
tion densities and grown in RPMI 1640 medium supplemented with 5%
fetal bovine serum for 48 h. We measured cell populations using sulforho-
damine B optical density measurement assay. The doubling time constant k
was calculated using the equation: N/No = ekt, where No is optical density
for control (untreated) cells at time zero, N is optical density for control cells
after 48-h incubation, and t is 48 h. The same equation was then used with the
derived k to calculate the doubling time t by setting N/No = 2. For a given cell
line, we obtained No and N values by averaging optical densities (N>6,000)
obtained for each cell line for a year’s screening. Data and experimental details
are available (http://dtp.nci.nih.gov).
Preparation and hybridization of fluorescent labelled cDNA. For each
comparative array hybridization, labelled cDNA was synthesized by reverse
transcription from test cell mRNA in the presence of Cy5-dUTP, and from
the reference mRNA with Cy3-dUTP, using the Superscript II reverse-tran-
scription kit (Gibco-BRL). For each reverse transcription reaction, mRNA
(2 µg) was mixed with an anchored oligo-dT (d-20T-d(AGC)) primer (4
µg) in a total volume of 15 µl, heated to 70 °C for 10 min and cooled on ice.
To this sample, we added an unlabelled nucleotide pool (0.6 µl; 25 mM
each dATP, dCTP, dGTP, and 15 mM dTTP), either Cy3 or Cy5 conjugated
dUTP (3 µl; 1 mM; Amersham), 5×first-strand buffer (6 µl; 250 mM Tris-
HCL, pH 8.3, 375 mM KCl, 15 mM MgCl2), 0.1 M DTT (3 µl) and 2 µl of
Superscript II reverse transcriptase (200 µ/µl). After a 2-h incubation at 42
°C, the RNA was degraded by adding 1 N NaOH (1.5 µl) and incubating at
70 °C for 10 min. The mixture was neutralized by adding of 1 N HCL (1.5
µl), and the volume brought to 500 µl with TE (10 mM Tris, 1 mM EDTA).
We added Cot1 human DNA (20 µg; Gibco-BRL), and purified the probe
by centrifugation in a Centricon-30 micro-concentrator (Amicon). The
two separate probes were combined, brought to a volume of 500 µl, and
concentrated again to a volume of less than 7 µl. We added 10 µg/µl
poly(A) RNA (1 µl; Sigma) and tRNA (10 µg/µl; Gibco-BRL) were added,
and adjusted the volume to 9.5 µl with distilled water. For final probe
preparation, 20×SSC (2.1 µl; 1.5 M NaCl, 150 mM NaCitrate, pH 8.0) and
10% SDS (0.35 µl) were added to a total final volume of 12 µl. The probes
were denatured by heating for 2 min at 100 °C, incubated at 37 °C for
20–30 min, and placed on the array under a 22 mm×22 mm glass coverslip.
We incubated slides overnight at 65 °C for 14–18 h in a custom slide cham-
ber with humidity maintained by a small reservoir of 3×SSC. Arrays were
washed by submersion and agitation for 2–5 min in 2×SSC with 0.1% SDS,
followed by 1×SSC and then 0.1×SSC. The arrays were “spun dry” by cen-
trifugation for 2 min in a slide-rack in a Beckman GS-6 tabletop centrifuge
in Microplus carriers at 650 r.p.m. for 2 min.
Array quantitation and data processing. Following hybridization, arrays
were scanned using a laser-scanning microscope (ref. 17; http://cmgm.
stanford.edu/pbrown). Separate images were acquired for Cy3 and Cy5. We
carried out data reduction with the program ScanAlyze (M.B.E., available
at http://rana.stanford.edu/software). Each spot was defined by manual
positioning of a grid of circles over the array image. For each fluorescent
image, the average pixel intensity within each circle was determined, and a
local background was computed for each spot equal to the median pixel
intensity in a square of 40 pixels in width and height centred on the spot
centre, excluding all pixels within any defined spots. Net signal was deter-
mined by subtraction of this local background from the average intensity
for each spot. Spots deemed unsuitable for accurate quantitation because
of array artefacts were manually flagged and excluded from further analy-
sis. Data files generated by ScanAlyze were entered into a custom database
that maintains web-accessible files. Signal intensities between the two fluo-
rescent images were normalized by applying a uniform scale factor to all
intensities measured for the Cy5 channel. The normalization factor was
chosen so that the mean log(Cy3/Cy5) for a subset of spots that achieved a
minimum quality parameter (approximately 6,000 spots) was 0. This effec-
tively defined the signal-intensity-weighted ‘average’ spot on each array to
have a Cy3/Cy5 ratio of 1.0.
Cluster analysis. We extracted tables (rows of genes, columns of individual
microarray hybridizations) of normalized fluorescence ratios from the data-
base. Various selection criteria, discussed in relation to each data set, were
applied to select subsets of genes from the 9,703 cDNA elements on the
arrays. Before clustering and display, the logarithm of the measured fluores-
cence ratios for each gene were centred by subtracting the arithmetic mean of
all ratios measured for that gene. The centring makes all subsequent analyses
independent of the amount of each gene’s mRNA in the reference pool.
We applied a hierarchical clustering algorithm separately to the cell lines
and genes using the Pearson correlation coefficient as the measure of simi-
larity and average linkage clustering3,19–21. The results of this process are
two dendrograms (trees), one for the cell lines and one for the genes, in
which very similar elements are connected by short branches, and longer
branches join elements with diminishing degrees of similarity. For visual
display the rows and columns in the initial data table were reordered to
conform to the structures of the dendrograms obtained from the cluster
analysis. Each cell in the cluster-ordered data table was replaced by a graded
colour (pure red through black to pure green), representing the mean-
adjusted ratio value in the cell. Gene labels in cluster diagrams are dis-
played here only for genes that were represented in the microarray by
sequence-verified cDNAs. A complete software implementation of this
process is available (http://rana.stanford.edu/software), as well as all clus-
tering results (http://genome-www.stanford.edu/nci60).
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